Leerink Swann Upgrades Merck & Co (MRK) to Outperform; Near-Term Risks Already Factored In
More News related to MRK
- Merck (MRK) Declares $0.38 Quarterly Dividend; 4.1% Yield; Announces $3B Common Buyback
- Merck Announces Quarterly Dividends and New $3 Billion Share Repurchase Program
- PROLOR Biotech Reports Merck Receives Positive Regulatory Opinion for European Marketing of Long-Acting CTP-Modified Fertility Treatment ELONVA(R) (FSH-CTP)
- PROLOR Biotech Reports Merck Receives Positive Regulatory Opinion for European Marketing of Long-Acting CTP-Modified Fertility Treatment ELONVA(R) (FSH-CTP)
- Merck Wins Summary Judgment in Second Federal Bellwether Case Involving FOSAMAX(R) (alendronate sodium)
More News related to Upgrades
- Sign of the Times: U.S. Mint Has To Temporarily Suspend Sales of One Ounce Gold Coins Due to Demand
- Central Banks Continue Snapping Up Gold, Sri Lanka Buys 10 Metric Tons From IMF
- Holiday Retail Match-Up: Wal-Mart vs. Amazon... Who Will Come Out on Top?
- Research Firm Questions Surge In Origin Agritech (SEED)
- Starbucks (SBUX) Bets Big On China
Leerink Swann upgrades Merck & Co (NYSE: MRK) from Market Perform to Outperform.
Leerink analyst says, "We are upgrading MRK to Outperform, reflecting our growing comfort that near-term risks (ARBITER 6, Temodar U.S. patent challenge, Remicade/Simponi arbitration with JNJ) are quantifiable and largely factored into the MRK's current valuation and Street expectations. A MEDACorp cholesterol survey (published today) suggests another leg down for Zetia/Vytorin in the U.S. from ARBITER 6, and headlines associated with a potential editorial from Steve Nissen may spark weakness in MRK shares, but we believe the current valuation already implies the loss of >50% of the cholesterol franchise, 100% of U.S. Temodar sales, and up to 30% of Remicade/ Simponi profits. Our industry contacts believe chances of a favorable settlement with JNJ are good and that Merial/Intervet FTC overlap may be overestimated and cost synergies underestimated. Given these opportunities coupled with MRK's substantial late-stage pipeline, we recommend that investors use near-term liquidity to build, or add to, a position in MRK."
To see more analyst ratings on MRK Click Here.
Merck & Co., Inc. provides products for human and animal health in the United States and internationally.
Related Categories
UpgradesStocks Mentioned
+0.35Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
